+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
ISHITADR ISHITADR

Ishita Drugs & Industries Share Price

₹70.01 -2.74 (-3.77%)

23 Oct, 2026 4:01 PM (IST)

Ishita Drugs & Industries live price: ₹70.01. It opened at ₹73 vs previous close ₹73; intraday high/low: ₹73/₹69. The 50 & 200 DMA stand at ₹74.40/₹75.00.

Ishita Drugs & Industries Performance

  • Today's Low
  • ₹69
  • Today's High
  • ₹73
  • 52 Week Low
  • ₹66
  • 52 Week High
  • ₹91
  • Open Price₹73
  • Previous Close₹73
  • Volume211
  • 50 DMA₹74.40
  • 100 DMA₹74.60
  • 200 DMA₹75.00

Ishita Drugs & Industries Chart

Investment Returns

  • Over 1 Month -4.27%
  • Over 3 Month -5.46%
  • Over 6 Month -13.26%
  • Over 1 Year -5.84%

Smart Investing Starts Here Start SIP with Ishita Drugs & Industries for Steady Growth!

Invest Now

Ishita Drugs & Industries Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 29.6
  • PEG Ratio
  • -1
  • Market Cap Cr
  • 21
  • P/B Ratio
  • 1.8
  • Average True Range
  • 3.6
  • EPS
  • 2.4
  • Dividend Yield
  • 0
  • MACD Signal
  • -
  • RSI
  • 42.9
  • MFI
  • 85.88

Latest Stock News Updates

Ishita Drugs & Industries Ltd - 524400 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Compliance Certificate under regulation 74(5) of SEBI(Depositories and Participants) Regulations, 2018 for the quarter ended 30th September, 2026 as attached.

Ishita Drugs & Industries Ltd - 524400 - Announcement under Regulation 30 (LODR)-Change in Management

1. Approval of re-appointment of Mrs. Abha Agrawal (DIN: 01589479) as a Non Executive Non-Independent Director of the Company post attaining the age of 75 years , and who retires by rotation, being eligible offers herself for re-appointment. 2. Approval of re-appointment of M/s. Jaymin Shah & Assocites, Chartered Accountants as the statutory auditor of the company for the FY 2026-27

Ishita Drugs & Industries Ltd - 524400 - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s

Re-appointment of M/s. Jaymin Shah & Associates, Chartered Accountants (FRN: 129406W) as a statutory Auditor of the Company for the FY 2026-27.

Ishita Drugs & Industries Financials

Ishita Drugs & Industries Technicals

EMA & SMA

Current Price
₹70.01
-2.74 (-3.77%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹74.50
  • 50 Day
  • ₹74.40
  • 100 Day
  • ₹74.60
  • 200 Day
  • ₹75.00

Resistance and Support

70.6 Pivot Speed
  • R3 75.90
  • R2 74.30
  • R1 72.20
  • S1 68.40
  • S2 66.80
  • S3 64.70

Ishita Drugs & Industries Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-09-22 To consider raising of funds
2026-08-08 Quarterly Results
2026-05-30 Audited Results
2026-02-07 Quarterly Results
2025-11-11 Quarterly Results

Ishita Drugs & Industries Shareholding Pattern

50.04%
49.96%
0%

About Ishita Drugs & Industries

Ishita Drugs & Industries is engaged in the business of manufacturing of various APIs (Active Pharma Ingredients) and drug intermediates. It has built up a reputation as a manufacturer of “high quality” products and is known for its ethical dealings in business. The company supplies its products to leading pharmaceutical companies of India. The products are also being exported to various countries across the world. View More
  • NSE Symbol
  • ISHITADR
  • BSE Symbol
  • 524400
  • ISIN
  • INE806D01016

Similar Stocks to Ishita Drugs & Industries

Ishita Drugs & Industries FAQs

Ishita Drugs & Industries share price is ₹70 As on 25 October, 2026 | 22:15

The Market Cap of Ishita Drugs & Industries is ₹20.9 Cr As on 25 October, 2026 | 22:15

The P/E ratio of Ishita Drugs & Industries is 29.6 As on 25 October, 2026 | 22:15

The PB ratio of Ishita Drugs & Industries is 1.8 As on 25 October, 2026 | 22:15

The 52 week High & Low of Ishita Drugs & Industries is ₹90.8/₹66 respectively As on 25 October, 2026 | 22:15

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23